Recently, Oncoceutics’ VP of Research and Development Dr. Joshua Allen presented at a webinar hosted by DiscoverX, a leader in GPCR screening.
G protein-coupled receptors (GPCRs) are the most commonly exploited drug target in modern medicine. These complex transmembrane receptors control several signaling pathways that are critical for cancer cells and are frequently hijacked by malignant cells. In recent years, researchers have increasingly implicated specific GPCRs as promising therapeutic targets for oncology, resulting in an increased focus on targeting these receptors. There is also an increasing appreciation that pharmacological engagement of GPCRs provides an opportunity to safely block an array of diverse oncogenic signals.
This webinar highlighted:
- Opportunities and challenges for targeting GPCRs in oncology
- Examples of GPCR-targeting investigational therapies for oncology
- Imipridones, selective GPCR-targeting small molecules, that are in preclinical and clinical development for oncology
A recording of the webinar can be found here.